How is Belimumab dosed?
The recommended dose for adults with systemic lupus erythematosus (SLE) is 100 mg administered intravenously (into a vein) over one hour every four weeks. For the treatment of lupus nephritis, the dose may be higher, up to 200 mg administered intravenously over one hour every four weeks. In some cases, patients may be able to administer the medication subcutaneously (under the skin) at home, following proper training from a healthcare professional. The subcutaneous dose is usually 50 mg per injection, administered once every two weeks. The exact dose and dosing schedule may vary depending on the individual patient's needs and medical history.
What is the dosage form of Belimumab?
The dosage forms of belimumab are solution and powder for solution.
How is Belimumab administered?
Belimumab is administered through a needle placed into one of the veins or as a shot under the skin, usually in the stomach or thighs. It can be given by a nurse or other trained health professional in a medical facility, or it may be prepared and injected by the patient or their caregiver at home, following proper training and understanding of the usage. If given through a vein in the arm, it must be injected slowly by a doctor, and the IV tube will need to stay in place for 1 hour.
What are common precautions when taking Belimumab?
Common precautions when taking belimumab include:
- History of cancer, depression, mental illness, infections, or a weak immune system: Use with caution, as belimumab may worsen these conditions or lower the body's ability to fight infections.
- Multiple drug allergy: May increase the risk of an allergic reaction to belimumab.
- Proper use: Belimumab must be administered by a trained health professional in a medical facility, either through a vein or as a subcutaneous shot. It is important to understand how to use the medicine properly.
- Immunizations: Avoid any immunizations without your doctor's approval during treatment with belimumab and for 30 days before starting treatment, as it may lower the body's resistance and the vaccine may not work as intended.
- African-American or African ancestry: Belimumab may not work as effectively in African-American patients and may require additional caution. Discuss your concerns with your doctor.
- Infections and cancer risk: Belimumab may increase the risk of developing infections, including PML, and increase the risk of cancer. Contact your doctor immediately if you experience any symptoms or side effects.
- Infusion reactions: Belimumab may cause infusion reactions, which can be life-threatening. Inform your healthcare provider immediately if you experience any signs of an infusion reaction, such as fever, chills, dizziness, or difficulty breathing.